Stock Ratings / Health Care / TENX / dividends

MNOV (30) TELO (34) ZYBT (40) OSTX (42) ⌘ Pro Terminal →

Tenax Therapeutics Inc. (TENX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.79 -3.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.77

Tenax Therapeutics Inc. (TENX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $69.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TENX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TENX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Tenax Therapeutics Inc. (NASDAQ: TENX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.79 (-3.76% 1D, market cap $69.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TENX ranks #558 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TENX compare to MNOV and TELO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TENX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MNOV (Medicinova Inc) holds a E grade (30/100 RQD, P/E 5.7x, ROIC -35.0%, cap $68.9M) and TELO (Telomir Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $71.0M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TENX?

▼

Per TENX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000034956), Tenax Therapeutics Inc. generated $0 in revenue, -$52.6M in net income, and -$35.8M in free cash flow against $104.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.77 (-0.87%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TENX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY TENX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (38% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 44.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.87-27.3% Next Q

Q2 (-2Q)

Grade D$1.36+26.5% Next Q

Q3 (-1Q)

Grade D$1.72+4.1% Next Q

Current

Grade D-$1.79-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TENX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TENX currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.84) and Max Pain ($1.88) forces dealer call-delta covering toward $20.37.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TENX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TENX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TENX)

✓Walkthrough of TENX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TENX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.35%▲ RESISTANCE BREAKOUT

2026-10-30O $1.83H $1.85L $1.73C $1.79VOL 885.7K

RES: $1.73SUP: $1.37SMA50: $1.84SMA200: $10.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TENX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TENX Butterfly Map → + Track TENX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TENX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TENX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TENX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TENX)

Health Care Rank #558 of 1016 ⚔️ MNOV vs TENX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TENX vs. MNOV, TELO, ZYBT, OSTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tenax Therapeutics Inc. (TENX) ranks #558 by composite RQD confidence (39/100, grade D-) and #708 by equity capitalization ($69.6M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with TENX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TENX ACTIVE Tenax Therapeutics Inc.	D-	39/100	—	—	-35.0%	-3.76%	$69.6M	Benchmark Subject
MNOV Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	/mnov-vs-tenx →
TELO Telomir Pharmaceuticals Inc.	E	34/100	—	—	-35.0%	-3.01%	$71.0M	/telo-vs-tenx →
ZYBT Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	/zybt-vs-tenx →
OSTX OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	/ostx-vs-tenx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000034956

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenax Therapeutics Inc. (TENX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$52.6M, operating cash flow of -$35.8M, and free cash flow of -$35.8M (-141.7% YoY). On the balance sheet, TENX closed FY2025 with $104.2M in total assets against $0 in total debt (Altman Z-Score: 0.23, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$52.6M	-$35.8M	-$35.8M	$104.2M	—
FY2024 (FY)	2024-12-31	$0	-$17.6M	-$14.8M	-$14.8M	$96.7M	—
FY2023 (FY)	2023-12-31	$0	-$7.7M	-$5.9M	-$5.9M	—	—

3. TENX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TENX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TENX compare to MNOV and TELO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TENX?

Where is TENX trading relative to its 50-day, 200-day, and 52-week technical levels?

TENX last traded at $1.79 (-3.76% on volume of 888,084 shares), positioning the stock -2.72% below its 50-day simple moving average ($1.84) and -82.22% below its 200-day simple moving average ($10.07). Across its 52-week range of $1.31 to $19.40, TENX sits at the 2.7% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.57 to $2.01).

TENX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TENX pay a dividend and is it safe?

Tenax Therapeutics Inc. (TENX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TENX RQD Cockpit TENX 12M Forecast TENX Earnings & Move TENX Dividends & DRIP TENX Insiders & 13F TENX Whale Options TENX Profit Sankey TENX News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TENX — Tenax Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Tenax Therapeutics Inc. (TENX) carries a composite score of 39/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $1.79 (-3.76%). Fundamental cash generation scores 3/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 9/20, insider conviction scores 5/20, macro regime alignment scores 15/20 (Beta 1.00), and forensic balance-sheet protection scores 7/20 (Altman Z-Score 0.23, Piotroski F-Score 2/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $1.31 – $19.40.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TENX is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

TENX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tenax Therapeutics Inc. (TENX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TENX Debate Forum (3) ↓

🔴 RISK WATCH Yahoo • 8d ago

Tenax Therapeutics (TENX) Stock Fair Value Falls After Cautious Analyst Calls On LEVEL Data

The latest analyst update on Tenax Therapeutics trims the fair value estimate from US$12.56 to US$9.63, a reduction of about 23% in the modeled price target. This cut lines up with more cautious Street commentary after t

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 58d ago

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients wit

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 62d ago

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, w

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 65d ago

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% r

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 83d ago

Tenax Therapeutics’ stock crashes on Phase III trial failure

Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 83d ago

Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103

The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a r

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 94d ago

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TENX Bull vs. Bear Conversation Board — What's Your Call at $1.79?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TENX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.58 (-11.7%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TENX (D- • RQD 39/100) a Buy at $1.79?

Welcome to the TENX (Tenax Therapeutics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.43 (-20.1%)

Spot @ $1.79

Pump the brakes on TENX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TENX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Tenax Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.11 (+17.9%)

Spot @ $1.79

TENX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TENX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.79 (52-wk range $1.31 - $19.40), any beat on forward guidance forces shorts and underweight funds to chase.